Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab plus Nivolumab with Chemotherapy vs Nivolumab with Chemotherapy in First-Line Stage IV or Recurrent NSCLC
2023-508372-10-00Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) comparing Relatlimab plus Nivolumab plus Chemotherapy with Nivolumab plus Chemotherapy (2 arms). Primary endpoints: Part 1 - Treatment-related adverse events leading to discontinuation within 12 weeks after first dose and Part 2 - Objective response rate per RECIST v1.1 by BICR. Started May 2024; status: completed.
02
Drugs
nivolumabrelatlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-508372-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508372-10-00.